Neutropenia Biologic Drug Treatment Market

?Neutropenia is a clinical condition characterized by a decrease in neutrophil count in the blood, resulting in a higher risk of developing serious infections. A neutrophil is a type of white blood cell, which helps in fighting infections. The major causes of neutropenia include cancer chemotherapy, infections, bone marrow disorders, autoimmune disorders, and the use of specific drugs.?

Neutropenia Biologic Drug Treatment Market contains market size and forecasts of Neutropenia Biologic Drug Treatment in Global, including the following market information:

Global Neutropenia Biologic Drug Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Neutropenia Biologic Drug Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

By Drug Type Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Neutropenia Biologic Drug Treatment include Teva Pharmaceutical, Amgen, Sanofi, Mylan(Fulphila), Kyowa Kirin, Novartis, Spectrum Pharmaceuticals, Pfizer and Baxter International, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Neutropenia Biologic Drug Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Neutropenia Biologic Drug Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Neutropenia Biologic Drug Treatment Market Segment Percentages, by Type, 2021 (%)

By Drug Type

Filgrastim

Pegfilgrastim

Lenograstim

Lipegfilgrastim

Sargramostim

By Treatment Type

Antibiotic Drugs

Granulocyte-Colony-Stimulating Factor (G-CSF)

Antifungal Drugs

Others

Global Neutropenia Biologic Drug Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Neutropenia Biologic Drug Treatment Market Segment Percentages, by Application, 2021 (%)

Retail Pharmacies

Hospital Pharmacies

Online Pharmacies

Global Neutropenia Biologic Drug Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Neutropenia Biologic Drug Treatment Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Neutropenia Biologic Drug Treatment revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Neutropenia Biologic Drug Treatment revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Teva Pharmaceutical

Amgen

Sanofi

Mylan(Fulphila)

Kyowa Kirin

Novartis

Spectrum Pharmaceuticals

Pfizer

Baxter International

Partner Therapeutics(Leukine)

BeyondSpring Pharmaceuticals

Cellerant Therapeutics

Enzychem Lifesciences Corporation

Myelo Therapeutics

Generon